Company Overview - Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing innovative therapies for cardiometabolic and rare/orphan diseases [2] - The company markets two oral, once-daily, non-statin therapies aimed at patients struggling to maintain low-density lipoprotein cholesterol (LDL-C) levels and at risk of cardiovascular disease [2] Market Position and Strategy - Esperion has a broad U.S. commercial infrastructure and has received global approvals in over 40 countries, positioning itself as a partner-of-choice for global innovators seeking U.S. market access through various collaboration opportunities [3] - The company is advancing its expertise in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases [3] Upcoming Events - Esperion will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, at 9:30 a.m. ET, with a live webcast available on its website [1]

Core Insights - Esperion reported a total revenue growth of 21% year-over-year (Y/Y) to $403.1 million for FY25, with U.S. net product revenue increasing by 38% Y/Y to $159.6 million [1][14] - The company achieved a significant Q4 2025 total revenue growth of 144% Y/Y to $168.4 million, with U.S. net product revenue also growing approximately 38% Y/Y to $43.7 million [1][14] - Esperion announced an agreement to acquire Corstasis Therapeutics, which is expected to enhance its cardiovascular franchise and align with its long-term strategic vision, Vision 2040 [1][4][3] Financial Performance - For Q4 2025, total revenue was $168.4 million, compared to $69.1 million in Q4 2024, marking a 144% increase [14] - Full-year revenue for 2025 reached $403.1 million, up from $332.3 million in 2024, reflecting a 21% increase [14] - U.S. net product sales for Q4 2025 were $43.7 million, up from $31.6 million in Q4 2024, a 38% increase [22] - Collaboration revenue for Q4 2025 was $124.7 million, a 232% increase from $37.6 million in Q4 2024 [22] Market Expansion and Strategic Initiatives - The acquisition of Corstasis Therapeutics is aimed at expanding Esperion's cardiovascular product offerings, particularly with the FDA-approved Enbumyst nasal spray [4][5] - Esperion's U.S. cardiovascular business showed strong momentum, with retail prescription equivalents growing 34% Y/Y and 11.3% quarter-over-quarter [6] - The company is focused on deeper U.S. market penetration and geographic expansion through partnerships, with a goal to enhance its product offerings and market access [3][8] Research and Development - Esperion is advancing its R&D pipeline, including the nomination of ESP-2001 for the treatment of primary sclerosing cholangitis, which represents a potential market opportunity exceeding $1 billion annually [15] - The company plans to develop oral triple combination lipid-lowering tablets, expected to be commercialized in 2027, which could rival existing therapies [10][11] Operational Highlights - Esperion's cash and cash equivalents as of December 31, 2025, totaled $167.9 million, an increase from $144.8 million in 2024 [20] - The company reported a net income of $61.8 million for Q4 2025, compared to a net loss of $21.3 million in Q4 2024 [18][19] - Selling, general, and administrative expenses for Q4 2025 were $41.4 million, a 12% increase from $36.9 million in Q4 2024, primarily due to increased legal costs [22]

Core Insights - Esperion reported preliminary full-year 2025 U.S. net product sales of $156 to $160 million, reflecting a 35% to 38% increase compared to 2024 [1] - The company anticipates total preliminary revenue of $400 to $408 million for 2025, marking a 20% to 23% increase from the previous year, and a 55% to 59% increase when excluding one-time milestones [1] - Esperion introduced its Vision 2040 growth strategy, aiming to evolve into a multi-product, sustainable, innovation-driven global pharmaceutical company [2][4] Financial Performance - Cash and cash equivalents at year-end 2025 are approximately $168 million [1] - Q4 retail prescription equivalents grew by 34% year-over-year and 11.3% quarter-over-quarter [1] - The company expects operating expenses for full-year 2026 to be between $210 million and $245 million [1][14] Vision 2040 Strategy - Vision 2040 aims to establish Esperion as a leader in cardiometabolic indications and expand its pipeline into rare hepatic and renal diseases [4][6] - The strategy includes plans to develop at least five marketed products and a robust pipeline addressing unmet medical needs [4] - Esperion intends to leverage its commercial infrastructure for partnerships, acquisitions, and co-promotion opportunities [5] U.S. Commercial Strategy - NEXLETOL® and NEXLIZET® are FDA-approved for cardiovascular disease prevention, targeting over 70 million patients in the U.S. [7] - The company is focusing on the statin intolerant or resistant market, which constitutes approximately 30% of the overall market [8] - Esperion has strengthened access and reimbursement support for its products, achieving over 90% coverage among commercial lives and Medicare beneficiaries [11] Global Expansion - Esperion has made significant progress in expanding its bempedoic acid products internationally, treating over 600,000 patients across 30 EU countries [12] - The company secured regulatory approval for NILEMDO in France and is advancing oral triple combination lipid-lowering tablets [12] R&D Pipeline - Esperion is advancing its ACLY-focused pipeline, targeting multiple life-threatening diseases with next-generation inhibitors [13][17] - The company nominated ESP-2001 for preclinical development, which addresses primary sclerosing cholangitis and represents a potential market opportunity exceeding $1 billion annually [17] Financial Flexibility - Esperion completed a $75 million capital raise in 2025 to support commercial expansion and pipeline development [14]

Core Insights - Esperion reported preliminary full-year 2025 U.S. net product sales of $156 to $160 million, reflecting a 35% to 38% increase compared to 2024 [1] - Total preliminary revenue is expected to be between $400 million and $408 million, marking a 20% to 23% increase from 2024, and a 55% to 59% increase when excluding one-time milestones [1] - The company introduced its Vision 2040 growth strategy, aiming to evolve into a multi-product, sustainable, innovation-driven global pharmaceutical company [2][4] Financial Performance - Esperion's cash and cash equivalents at year-end 2025 are approximately $168 million [1] - The company expects operating expenses for full-year 2026 to be between $210 million and $245 million [1][14] - A capital raise of $75 million was completed in 2025 to enhance financial flexibility [14] Product and Market Strategy - The U.S. commercial strategy focuses on NEXLETOL and NEXLIZET, which are approved for cardiovascular disease prevention [7] - Esperion's commercialization efforts are targeting the statin intolerant or resistant market, which constitutes about 30% of the overall market [8] - The company plans to introduce two triple combination products that could lower LDL-C by over 60%, potentially rivaling existing therapies [11] Global Expansion - Esperion has expanded its bempedoic acid products to over 30 countries in the EU, treating more than 600,000 patients [12] - The company has secured regulatory approvals in key markets, including France and Japan, enhancing its global footprint [12][16] R&D Pipeline - Esperion is advancing its ACLY-focused pipeline, targeting multiple life-threatening diseases with next-generation inhibitors [13] - The company nominated ESP-2001 for preclinical development, which addresses primary sclerosing cholangitis and represents a potential market opportunity exceeding $1 billion annually [17] Strategic Initiatives - Esperion has reached settlement agreements with four key ANDA filers to restrict generic entry until April 2040, strengthening its market position [11] - The company has enhanced access and reimbursement support for its products, achieving over 90% coverage among commercial lives and Medicare beneficiaries [11]